5 Treatment Options for Small Cell Lung Cancer Part 3 #sharecare #shorts

Dr Susanne Arnold talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase II study looking into Carfilzomib and irinotecan in relapsed small cell lung cancer.

She explains that there were two cohorts: platinum sensitive cancers and platinum resistant cancers.

Dr Arnold reports that in both cohorts at 6 months the overall survival was 59% for the platinum sensitive cohort and 54% for the platinum resistant cohort.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.phps

Dr Julia Rotow talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using concurrent osimertinib plus gefitinib for treating EGFR-mutated NSCLC.

The EGFR TKI osimertinib is active against the acquired gefitinib-resistant mutation EGFR T790M, as is gefitinib against the osimertinib-resistant EGFR C797S. Preclinical evidence suggests dual EGFR inhibition with gefitinib + osimertinib may delay emergence of acquired resistance.

Dr Rotow outlines the trial design and results, and how this regimen will impact clinical practice.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

Like too many of us, Brian Lanman has lost loved ones to cancer.

But as a director of research in the medicinal chemistry department at Amgen, he and his colleagues are fighting back.

By doing things that were once thought impossible, researchers like Brian are working towards a new generation of cancer treatments.

In this partnership with Politico Focus, we’re reminded that true innovation pushes scientists to go somewhere they haven’t before.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the application of the concept “oncogene addiction”, which postulates that a cancer cell exhibits dependence on a single oncogenic pathway or protein for its sustained proliferation or survival, in the development of targeted therapies for non-small cell lung cancer (NSCLC).

Prof Benjamin Besse (Institut Gustave Roussy, Villejuif, France) and Dr Alex Spira (Virginia Cancer Specialists Research Institute, Fairfax, USA) discuss the latest developments in EGFR-mutated non-small cell lung cancer (NSCLC) presented at ASCO 2020.

Prof Besse begins by outlining the results of ADARURA study, which investigated the use of osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection. Dr Spira states that the disease-free survival (DFS) achieved in these patients is profound and potentially practice-changing, but acknowledges there is some debate surrounding the immaturity of overall survival data.

The experts also highlight the latest results of CHRYSALLIS trial, which is an ongoing phase I trial investigating amivantamab, an anti-EGFR-MET bispecific antibody, in NSCLC patients with EGFR exon 20 mutations.

Prof Besse and Dr Spira conclude by discussing the outcomes in patients with advanced NSCLC and PDL-1 expression treated with immune checkpoint inhibitor monotherapy, and the evolving role of liquid biopsies.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php